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Background. In the general population, including those
with diabetes mellitus, coronary artery calcification (CAC)
correlates with atherosclerotic plaque burden. On the other
hand, accumulating evidence suggests that disordered mineral
metabolism significantly contributes to the vascular calcification
in individuals with end-stage renal disease (ESRD).
Methods. In order to determine the relative contribution of
accelerated atherosclerosis and disordered mineral metabolism
to CAC in chronic kidney disease, a pilot study of 90 patients
with type 2 diabetes mellitus was done [age, 40–65 years; nor-
moalbuminuria, N = 30; diabetic nephropathy (DN), N = 60].
Results. CAC was more prevalent and severe among individu-
als with DN compared to diabetic controls (odds ratio for preva-
lence 8.1, 95% CI 2.3–28.5; median scores, 66 vs. 4, P < 0.001).
None of the 4 measures of disordered mineral metabolism eval-
uated in this study (serum calcium, phosphorus, parathyroid
hormone, and 1,25 di-hydroxy vitamin D levels) correlated with
the prevalence or severity of CAC, or accounted for the differ-
ences seen between DN and diabetic controls. On the other
hand, the difference in the severity of hypertension (number
of antihypertensive medications) appeared to account for the
differences in CAC burden seen between DN and diabetic
controls.
Conclusion. This first such study of nondialyzed individuals
with DN suggests that, unlike ESRD patients, the high CAC
burden seen at earlier stages of diabetic chronic kidney dis-
ease is probably unrelated to disordered mineral metabolism.
The relationship between the severity of hypertension and CAC
burden provides a probable target for intervention in the pre-
dialysis phase of DN.
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Even though vascular calcification has long been recog-
nized as a complication of chronic kidney disease (CKD),
several factors have led to a renewed interest in this
problem. First, the availability of sensitive diagnostic
tools like electron beam computed tomography (EBCT)
has made it possible to conduct population-based inves-
tigations of the problem [1–3]. Second, recent studies
among patients undergoing maintenance dialysis have
demonstrated a relationship between various measures of
disordered mineral metabolism (e.g., serum calcium,
phosphorus and parathyroid hormone levels, and use of
calcium-based phosphate binders) and the severity of
vascular and valvular calcification [4–10]. Third, several
studies have demonstrated direct relationships between
elevated serum phosphorus or calcium-phosphorus prod-
uct levels and mortality among maintenance dialysis
patients [11–13]. Finally, the extent of vascular calcifica-
tion among patients undergoing maintenance hemodial-
ysis has been associated with an increase in all-cause and
cardiovascular mortality [14]. In contrast to the findings
among individuals with end-stage renal disease (ESRD),
the coronary artery calcification (CAC) score in the gen-
eral population, including among individuals with type 2
diabetes mellitus, correlates with atherosclerotic plaque
burden and predicts future fatal and nonfatal cardiovas-
cular outcomes [2, 15–17]. The contribution of acceler-
ated atherosclerosis and disordered mineral metabolism
to the high vascular calcification burden among individ-
uals with CKD has not been previously evaluated.
Studies among nondialyzed individuals with CKD have
the potential to enhance our understanding of the pro-
cesses that lead to the initiation and progression of vascu-
lar calcification. Our recent retrospective analyses have
demonstrated a high prevalence and severity of vascu-
lar and valvular calcification among nondialyzed indi-
viduals with diabetic nephropathy (DN) with an average
glomerular filtration rate of 49 mL/min/1.73m2 [18]. We
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undertook a pilot study to determine the relationship be-
tween the traditional cardiovascular and renal function-
related (including disordered mineral metabolism) risk
factors and the prevalence and severity of vascular calci-
fication among nondialyzed individuals with DN. In order
to minimize the confounding influence of age, individuals
between the ages of 40 to 65 years with type 2 diabetes
mellitus were studied.
METHODS
Patient recruitment and definition of DN and diabetic
controls
This was a pilot, cross-sectional study of CAC in a co-
hort of middle-aged, nondialyzed, individuals with type 2
diabetes mellitus. Three groups of 30 individuals were
studied (n = 90): Latinos with diabetes mellitus and
normo-albuminuria (diabetic controls), Latinos with DN,
and African Americans with DN. Subjects were recruited
from the inpatient and outpatient services of 2 public hos-
pitals in Los Angeles county, Califonia. The inclusion cri-
teria for the study were: (1) self-defined Latino or African
American race/ethnicity; (2) age, in completed years, be-
tween 40 and 65 years; and (3) meets the definition of DN
or diabetic controls as defined below. Individuals who had
progressed to end-stage renal disease requiring dialysis
were excluded; no other exclusion criteria were used for
the study. The data on 25 (DN, 15; diabetic controls, 10) of
these 90 subjects were included in a previous publication
[18].
Strict clinical criteria were used to define DN because
among individuals with type 2 diabetes mellitus and ei-
ther microalbuminuria or overt proteinuria, 2 major pat-
terns of renal injury are discernible: typical DN lesion
(mesangial expansion accompanied by arterial/arteriolar
nephrosclerosis) or isolated ischemic/hypertensive renal
lesion (without mesangial expansion) [19]. Over half the
individuals with type 2 diabetes mellitus and microal-
buminuria, and 10% to 20% of diabetics with overt
proteinuria do not have the typical DN lesion [20–25].
However, the higher the degree of proteinuria, the
greater the probability that the renal disease is caused
by the typical DN lesion [26]. Thus, in this study, DN was
deemed to be present using the criteria established by
the NIDDK-sponsored FIND study, and was defined
as the presence of 1 of the following: (1) renal biopsy
evidence of DN with overt proteinuria (urine protein
>0.5 mg/day or urine protein/creatinine ratio >0.5); (2)
diabetes duration ≥10 years and urine protein excretion
>2.5 g/day or protein creatinine ratio >2.5; or (3) diabetes
duration ≥5 years, presence of diabetic retinopathy, and
urine protein excretion >1.0 g/day or protein creatinine
ratio >1.0. The highest documented urine protein excre-
tion in the patient’s medical chart was used to determine
patient eligibility.
In order to minimize the confounding influence of du-
ration of diabetes mellitus, controls were defined as in-
dividuals with diabetes duration ≥10 years and urine
albumin <30 lg/min or <30 mg/day, or spot albu-
min/creatinine ratio <0.03. Of the 90 study participants, 9
reported to be positive for hepatitis C (DN, n = 8; diabetic
controls, n = 1).
Data collection and definition of risk factors
All eligible patients who consented to participate in
the study were scheduled for an outpatient clinic visit
at the General Clinical Research Center located at the
Harbor-UCLA Medical Center. The study participants
were asked to come in fasting (except medications), and
to bring in all the current prescribed or over-the counter
drugs that they were taking at the time of the visit. None
of the patients enrolled in the study had been prescribed
phosphate binders, vitamin D, or its analogs by their treat-
ing physicians at the time of the study visit. Blood pres-
sure was measured in duplicate using a size-appropriate
cuff after the subject had been seated with their back
against a chair for at least 5 minutes. The average of the
2 readings on the right arm was used for analyses.
A fasting blood sample was drawn on the day of the
study visit and analyzed for the following: serum lev-
els of electrolytes, blood urea nitrogen, creatinine, albu-
min, calcium, phosphorus, intact parathyroid hormone
(iPTH, Nichols 7–84 assay; normal range 10–65 pg/mL),
1,25 dihydroxy vitamin D (Nichols assay, normal range
24–65 pg/mL), and lipid panel (total, low-density, and
high-density cholesterol and triglycerides). Serum phos-
phorus, iPTH, and 1,25-dihydroxy vitamin D levels were
included in the study protocol only after the first 9 pa-
tients had been enrolled; thus, these data were available
for 51 subjects with DN, and 30 diabetic controls. The
subjects’ charts were reviewed to determine the worst
documented urine protein excretion, as indicated above,
and the most recently available value for glycosylated
hemoglobin (HbA1c).
All the data thus collected were used to determine the
prevalence and/or severity of traditional (nonmodifiable:
age, gender, family history of premature cardiovascular
disease; modifiable: hypertension, dyslipidemia, current
smoking, and obesity), renal-related [serum creatinine,
estimated glomerular filtration rate (GFR), serum cal-
cium, phosphorus, intact parathyroid hormone (iPTH),
and 1,25-dihydroxy vitamin D levels], and diabetes-
related [glycosylated hemoglobin (HbA1c) and duration
of type 2 diabetes mellitus] risk factors. Clinical evidence
of coronary artery disease (CAD) was defined as the
presence of 1 of the following: angina on the Rose ques-
tionnaire, history of myocardial infarction, or previous
revascularization.
A fatal/nonfatal ischemic cardiovascular event in a
first-degree male relative <45 years of age or female
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relative <55 years of age was used to classify the presence
of a family history of premature cardiovascular disease.
Hypertension was defined as present if the systolic blood
pressure was >140 mm Hg or diastolic blood pressure
>90 mm Hg during the study visit. Among individuals
with blood pressure <140/90 mm Hg, hypertension was
deemed to be present if they were being treated with
antihypertensive medications without antiproteinuric
properties. If the blood pressure was <140/90 mm Hg and
individuals were being treated with drugs with antipro-
teinuric properties, the medical charts were reviewed
to ascertain the pretreatment blood pressure. Dyslipi-
demia was defined as present if the low-density choles-
terol was >130 mg/dL or high-density cholesterol was
<40 mg/dL on the fasting lipid panel on the day of the
study visit, or the patient was being treated with lipid-
lowering medications. Three different measures of body
size were used: body mass index (kg/m2), waist-hip ra-
tio, and waist circumference. Since there was no relation-
ship between measures of body size and the key outcome
measures, only the data on body mass index are pre-
sented. GFR was estimated using the abbreviated Mod-
ification of Diet in Renal Disease (MDRD) equation
[GFR (mL/min/1.73 m2) = 186 × (age, years)−0.203 ×
(serum creatinine, mg/dL)−1.154 × 0.742, if female, × 1.21,
if African American] [27, 28].
Electron beam computed tomography
EBCT studies were performed on the same day as the
clinical and laboratory evaluation with a C-150 XL Ul-
trafast computed tomographic scanner (Imatron, South
San Francisco, CA, USA). The protocol used for data ac-
quisition has been described previously [29]. The scans of
all individuals were retrieved, and the CAC was scored
by a single, highly experienced technician using both
the Agatston as well as volumetric method [30, 31]. The
Agatston and volumetric scores were highly correlated
in each of the 3 groups studied (r = 0.99). Since most
of the published data are based upon Agatston scores,
only those data are reported. CAC was defined as be-
ing present if there was any detectable coronary artery
calcification (score > 0).
Statistical analyses
Data are expressed as mean ± SEM. Three sets of anal-
yses were performed. First, subject characteristics were
compared between diabetic controls and DN subjects,
second, associations of CAC with subject characteristics
among all subjects were examined, and third, the influ-
ence of factors on differences in CAC scores between DN
and control subjects was assessed.
Subject characteristics were individually compared be-
tween DN and control groups using chi-square tests
for categorical characteristics, analysis of variance
(ANOVA) or t tests for normally distributed continuous
characteristics, and Kruskal-Wallis tests for non-normally
distributed characteristics (CAC score, serum LDL and
HDL cholesterol, triglycerides, creatinine, phosphorus,
and iPTH levels).
Associations between CAC score and subject charac-
teristics were made with ANOVA or t test for categorical
characteristics, and with Pearson correlation for continu-
ous characteristics, using log-transformed values for non-
normally distributed variables. In order to log transform
the CAC scores, the conventional method of log10 (CAC
score + 1) was used. Trends in subject characteristics
over CKD stages were measured with contrasts for linear
trend in ANOVA for continuous variables, and with the
Cochran-Armitage test for categorical variables.
To assess the effect of factors associated with the
differences in the CAC score between DN and dia-
betic controls, ANOVA was performed. For this pur-
pose, each associated factor was categorized and included
with nephropathy status as factors in separate two-way
ANOVAs on log-transformed CAC scores. Geometric
mean CAC scores, adjusted for the associated factor, and
according to the categories of the factor, were calculated
from the ANOVAs.
Since this was a pilot study and the analyses were ex-
ploratory in nature, no formal corrections were made for
performing multiple statistical tests. A P value of < 0.05
was considered significant.
RESULTS
Patient characteristics
The clinical characteristics of the 90 patients (44
men) and the prevalence of traditional, renal-related
and diabetes-related risk factors are summarized in
Tables 1 and 2. The average 24-hour urine protein ex-
cretion among the 60 individuals with DN was 7.2 ±
0.9 g/day; the albumin creatinine ratio among the 30 di-
abetic controls was 0.012 ± 0.003 mg albumin/mg cre-
atinine. Except for higher serum triglycerides (Latinos
259 ± 54 vs. African Americans 145 ± 16 mg/dL; P =
0.02) and phosphorus (Latinos 4.8 ± 0.2 vs. African
Americans 4.0 ± 0.2 mg/dL; P = 0.007) among Latinos
with DN, there were no significant differences between
Latinos and African Americans with DN; thus, their data
were pooled for further analyses.
When compared to diabetic controls, individuals with
DN had a significantly higher prevalence of hypertension
(DN vs. controls, 97% and 73%, respectively, P = 0.001)
and a higher systolic blood pressure (158 ± 4 vs. 140 ±
4 mm Hg, P =0.002), despite an almost 3-fold higher num-
ber of antihypertensive medications at the time of clinic
visit (3.0 ± 0.2 vs. 1.2 ± 0.2, P < 0.001). Furthermore, in-
dividuals with DN had a significantly higher serum creati-
nine (2.7 ± 0.2 vs. 0.7 ± 0.0 mg/dL, P < 0.001), phosphorus
Mehrotra et al: Determinants of CAC in diabetics with and without nephropathy 2025
Table 1. Clinical characteristics and traditional cardiovascular risk
factors
Diabetic Diabetic
control nephropathy
Number of subjects 30 60
Age years 54 ± 1 55 ± 1
Gender (male/female) 13/17 31/29
Hypertension
Prevalence %c 73% 97%
Systolic BP mm Hgb 140 ± 4 158 ± 4
Diastolic BP mm Hg 77 ± 2 79 ± 2
Mean arterial pressure mm Hga 98 ± 2 105 ± 2
Antihypertensive medications No.c 1.2 ± 0.2 3.0 ± 0.2
Dyslipidemia
Prevalence % 80% 85%
Total cholesterol mg/dL 198 ± 7 200 ± 8
LDL cholesterol mg/dL 118 ± 7 117 ± 6
HDL cholesterol mg/dL 43 ± 3 44 ± 2
Triglycerides mg/dLd 190 ± 28 202 ± 29
Body size
Body mass index kg/m2 31.6 ± 1.2 31.1 ± 1.0
Medications
ACEI/ARB 63% 72%
Beta blockersa 27% 50%
Calcium channel blockersc 13% 52%
HMG CoA reductase inhibitors 33% 43%
Current smokers % 17% 22%
History of manifest CADe 23% 25%
Framingham Risk Score (10-year risk)% 9.3 ± 0.9 8.2 ± 1.3
Family history % 23% 14%
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor
blockers; HMG Co reductase inhibitors, hydroxy methyl glutarate coenzyme A
reductase inhibitors (“statins”).
Latino diabetic controls vs. pooled diabetic nephropathy: aP ≤ 0.05; bP ≤
0.01; cP ≤ 0.001.
Latino vs. African Americans with diabetic nephropathy: dP ≤ 0.05.
eDefined as a positive history for angina (on Rose questionnaire), myocardial
infarction, or revascularization.
(4.4 ± 0.2 vs. 3.7 ± 0.1 mg/dL, P = 0.001), and iPTH levels
(210 ± 34 vs. 46 ± 3 pg/mL, P < 0.001) and lower GFR
(39 ± 4 vs. 107 ± 5 mL/min/1.73m2, P < 0.001), serum
albumin (3.1 ± 0.1 vs. 3.7 ± 0.1 g/dL, P < 0.001), and
1,25-dihydroxy vitamin D (34 ± 2 vs. 49 ± 3 pg/mL, P <
0.001) levels when compared to diabetic controls. There
were no significant differences between the various mea-
sures of dyslipidemia, body size, smoking, family history
of premature cardiovascular disease, or diabetes-related
risk factors between the 2 groups. Similar results were
obtained when the African Americans with DN were ex-
cluded and analyses were restricted to Latinos with DN
and diabetic controls.
Among individuals with DN, 15 (25%) had clinical ev-
idence of CAD—angina, 6; history of myocardial infarc-
tion, 9; and previous revascularization, 5. Among diabetic
controls, 7 (23%) individuals had clinical CAD—angina,
4; history of myocardial infarction, 5; and previous revas-
cularization, 3.
Coronary artery calcification: Prevalence and severity
There was a high prevalence of CAC in individuals
with diabetes mellitus, irrespective of nephropathy status.
Table 2. Renal and diabetes-related characteristics in subjects with
and without nephropathy
Diabetic Diabetic
control nephropathy
Number of subjects 30 60
Urinary protein/albumin excretion 7.2 ± 0.9
24-hour protein g/day
Albumin-creatinine ratio mg/mg 0.012 ± 0.003
Renal function
Serum creatinine mg/dLc 0.7 ± 0.0 2.7 ± 0.2
Estimated glomerular filtration rate 107 ± 5 39 ± 4
mL/min/1.73m2 c
Divalent ion metabolism
Serum calcium mg/dL 9.6 ± 0.1 9.6 ± 0.1
Serum phosphorus mg/dLb,d 3.7 ± 0.1 4.4 ± 0.2
Serum parathyroid hormone pg/mLc 46 ± 3 210 ± 34
Serum 1,25 dihydroxyvitamin D 49 ± 3 34 ± 2
pg/mLc
Serum albumin g/dLc 3.7 ± 0.1 3.1 ± 0.1
Diabetes-related factors
Glycosylated hemoglobin % 8.6 ± 0.3 7.9 ± 0.3
Duration of diabetes mellitus years 15 ± 1 17 ± 1
Coronary artery calcification
Prevalence %c 63% 93%
Agatston Scoreb 4 (0, 125) 66 (8, 393)
Agatston Score >400 % 10% 25%
Latino diabetic controls vs. pooled diabetic nephropathy: aP ≤ 0.05; bP ≤
0.01; cP ≤ 0.001.
Latinos vs. African Americans with diabetic nephropathy: dP ≤ 0.01.
However, the prevalence was significantly higher among
individuals with DN compared to diabetic controls (93%
vs. 63%, respectively, P < 0.001; OR 8.1, 95% CI 2.3–
28.5). The CAC score was significantly higher among in-
dividuals with DN compared to diabetic controls [median
scores, DN 66 (8, 393) vs. controls 4 (0, 125), P <
0.001] (Fig. 1). Even when the analyses were restricted to
Latinos, both the prevalence and severity of CAC were
significantly higher among individuals with DN compared
to controls.
The CAC scores in this study population were com-
pared with the data obtained on 8673 nondiabetic indi-
viduals (5945 men and 2728 women) between the ages of
40 and 65 years who had no evidence of manifest CAD
and had undergone EBCT at Harbor-UCLA (Fig. 2A
and B). Of the 90 study subjects, 66 (73%) had a CAC
score that was greater than the 50th age- and gender-
matched percentile score, and 21 (23%) had scores that
were greater than the 90th percentile (P < 0.0001 for
each rate compared to nondiabetic controls). Similar re-
sults were obtained when the analyses were restricted to
the DN and diabetic controls with no evidence of mani-
fest CAD (71% and 19% above 50th and 90th percentile
score, respectively). Furthermore, individuals with DN
were significantly more likely to have scores greater than
50th percentile (82% vs. 57%, P = 0.01) or the 90th per-
centile (32% vs. 7%, P = 0.008) for age and gender, when
compared to diabetic controls.
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Fig. 1. Box-plots comparing the coronary artery calcification score
among diabetic controls and those with diabetic nephropathy. The bold
line reflects the median score, the upper and lower lines of the box rep-
resent the 25th and 75th percentile for the category, and lines represent
the extreme values for the coronary artery calcification score. The coro-
nary artery calcification score of controls (N = 30, score: 4 and 0 and 125,
median, 25th and 75th percentile, respectively) was significantly lower
than among individuals with diabetic nephropathy (N = 60, score: 66
and 8 and 393, median, 25th and 75th percentile, respectively) (P <
0.001).
Coronary artery calcification and risk factors: Univariate
analyses
The prevalence of CAC was significantly greater
among men when compared to women (93% vs. 74%,
P = 0.01). Although there were no significant differences
in systolic or diastolic blood pressure, individuals with
CAC were taking a significantly larger number of antihy-
pertensive medications at the time of the study visit com-
pared to those without (2.6 ± 0.2 vs. 1.2 ± 0.3, P < 0.001).
There was no significant difference in the prevalence of
CAC among individuals with or without a clinical history
of CAD, hypertension, dyslipidemia, or current smoking.
Moreover, there were no significant differences in any
measure of dyslipidemia or body size or Framingham risk
score in individuals with or without CAC.
To determine the correlates of the severity of CAC,
univariate analyses were performed after pooling the
data from all individuals with DN and diabetic controls
(N = 90). In this pooled analyses, the CAC score was
significantly positively associated with age (r = 0.28, P =
0.008), duration of diabetes mellitus (r = 0.26, P = 0.02),
the number of antihypertensive medications (r = 0.35,
P = 0.0006), and serum creatinine (r = 0.24, P = 0.02).
CAC was negatively associated with estimated GFR (r =
−0.24, P = 0.02). Males had significantly greater geomet-
ric mean CAC scores than females (58 vs.19, P = 0.03),
as did subjects with clinical evidence of CAD compared
to those without (106 vs. 23, P = 0.008), and DN subjects
compared to diabetic controls (57 vs. 11, P = 0.002). No
other factors, including those related to disordered min-
eral metabolism (serum levels of calcium, phosphorus,
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Fig. 2. (A and B) Scatter plots comparing the CAC scores among in-
dividuals with DN and controls to the 25th, 50th, 75th, and 90th per-
centile scores from 8673 nondiabetic individuals (5945 men and 2728
women) between the ages of 40 and 65 years, with non-evidence of man-
ifest CAD, and who have undergone EBCT scanning at Harbor-UCLA
Medical Center. The closed circles represent the individuals with DN,
and the open circles represent the diabetic controls. Individuals with
DN were significantly more likely to have scores greater than the 50th
percentile (82% vs. 57%, P = 0.01) or the 90th percentile (32% vs. 7%,
P = 0.008) for age and gender, when compared to diabetic controls.
iPTH, and 1,25-dihydroxy vitamin D) were significantly
associated with CAC score.
These analyses were repeated after excluding the
African Americans subjects with DN, and the same set
of factors was found to be significantly associated with
CAC score. Similarly, there was no significant relationship
between any measure of disordered mineral metabolism
and the CAC score, even when the data were analyzed
after excluding the African Americans with DN.
To further explore the relationship between estimated
GFR and CAC, the 60 subjects with DN were catego-
rized according to the stage of chronic kidney disease
(Table 3) [32]. As is evident, among individuals with DN
there was no significant difference in either the preva-
lence or the severity of CAC among individuals based
upon the stage of CKD.
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Table 3. Clinical characteristics and traditional cardiovascular risk factors in subjects with diabetic nephropathy, based upon estimated
glomerular filtration rate
CKD stage 1 2 3 4 5
GFR range mL/min/1.73m2 ≥90 60–89 30–59 15–29 <15
Number of subjects 4 12 14 21 9
Age years 49 ± 3 55 ± 2 56 ± 2 57 ± 1 53 ± 2
Gender (male/female) 4/0 5/7 8/6 9/12 5/4
Race/ethnicity (Latinos/African Americans) 0/4 8/4 7/7 10/11 5/4
Hypertension
Prevalence % 75% 92% 100% 100% 100%
Systolic BP mm Hg 155 ± 14 146 ± 7 156 ± 6 162 ± 7 172 ± 10
Diastolic BP mm Hg 85 ± 5 75 ± 3 80 ± 5 79 ± 3 80 ± 5
Mean arterial pressure mm Hg 109 ± 6 98 ± 4 105 ± 5 107 ± 3 111 ± 5
Antihypertensive medications No. 2.0 ± 1.1 2.8 ± 0.3 3.1 ± 0.3 3.0 ± 0.2 3.2 ± 0.4
Renal function
Serum creatinine mg/dLb 1.0 ± 0.1 1.1 ± 0.1 1.9 ± 0.1 3.2 ± 0.1 5.8 ± 0.5
Glomerular filtration rate 104 ± 8 71 ± 2 39 ± 2 21 ± 1 11 ± 1
mL/min/1.73m2b
Divalent ion metabolism
Serum calcium mg/dLa 9.8 ± 0.1 9.8 ± 0.1 9.8 ± 0.1 9.6 ± 0.1 9.1 ± 0.2
Serum phosphorus mg/dLb 3.1 ± 0.1 3.5 ± 0.3 4.2 ± 0.1 4.4 ± 0.1 6.3 ± 0.4
Serum parathyroid hormone pg/mLb 49 ± 8 70 ± 17 103 ± 17 261 ± 49 526 ± 146
Serum 1,25 dihydroxy vitamin D pg/mLa 45 ± 8 39 ± 3 32 ± 3 34 ± 2 22 ± 1
Serum albumin g/dL 3.4 ± 0.5 3.1 ± 0.1 3.1 ± 0.2 3.2 ± 0.1 2.9 ± 0.1
Coronary artery calcification
Prevalence % 100% 100% 93% 91% 89%
Agatston Score 138 (22,1015) 31 (6,81) 53 (5,386) 94 (19,473) 64 (3,565)
Agatston Score >400 % 25% 8% 21% 33% 33%
aP ≤ 0.01; bP ≤ 0.001.
Table 4. Adjusted and stratified CAC scoresa according to nephropathy status and nonrenal factors significantly associated with CAC score
among diabetics
Adjusted risk Diabetic control Diabetic nephropathy Geometric mean ratio:
factor Subjects (N = 30) (DN), (N = 60) DN/control P value
None All 11.1 (4.8–25.5) 57.2 (31.7–103) 5.2 (1.9–14.3) 0.002
Gender All 11.8 (5.2–26.8) 56.3 (31.5–100) 4.8 (1.7–13.0) 0.003
Women 3.2 (1.1–9.5) (N = 13) 55.7 (24.5–127) (N = 31) 17.2 (4.5–66.2) <0.0001
Men 55.2 (16.6–183) (N = 17) 58.6 (26.9–127) (N = 29) 1.1 (0.3–4.4) 0.93
Age All 11.2 (5.0–25.2) 49.9 (27.8–89.7) 4.4 (1.7–12.0) 0.004
Under 50 2.6 (0.8–8.8) (N = 10) 23.6 (8.5–65.5) (N = 14) 9.0 (1.9–43.6) 0.01
50–60 13.6 (3.6–51.4) (N = 12) 83.3 (35.3–196) (N = 29) 6.1 (1.3–30.0) 0.03
Over 60 49.3 (8.6–283) (N = 8) 62.3 (18.8–207) (N = 17) 1.3 (0.2–10.5) 0.82
#AH meds b All 19.7 (7.7–50.4) 39.5 (21.0–74.3) 2.0 (0.6–6.8) 0.26
0–1 5.5 (2.0–14.8) (N = 20) 18.5 (3.5–98.6) (N = 7) 3.4 (0.5–23.5) 0.21
2–3 45.1 (9.2–220) (N = 9) 63.1 (26.5–150) (N = 30) 1.4 (0.2–8.5) 0.71
4–5 43.2 (0.5–3969) (N = 1) 70.8 (27.6–182) (N = 23) 1.6 (0.0–166) 0.83
CAD All 16.6 (7.1–38.9) 83.4 (44.5–156) 5.0 (1.9–13.5) 0.002
w/o CAD 6.2 (2.6–15.1) (N = 23) 43.9 (23.2–82.8) (N = 45) 7.0 (2.4–21.0) 0.001
w/CAD 73.1 (10.8–496) (N = 7) 126 (34.2–468) (N = 15) 1.7 (0.2–17.6) 0.63
Diabetes duration All 11.9 (5.1–27.8) 53.8 (29.0–99.7) 4.5 (1.6–13.1) 0.006
<15 years 9.5 (3.4–26.4) (N = 19) 39.4 (14.8–105) (N = 21) 4.2 (1.0–17.2) 0.05
≥15 years 14.5 (3.4–62.5) (N = 11) 72.2 (32.6–160) (N = 37) 5.0 (0.9–26.1) 0.06
aGeometric least-squares mean CAC score (95% CI) from analyses of variance.
bNumber of antihypertensive medications.
Coronary artery calcification and risk factors:
Multivariate analyses
Given a near-universal presence of CAC among indi-
viduals with DN, multivariate adjustments for the differ-
ence in the prevalence of CAC between DN and diabetic
controls were not possible.
Table 4 presents mean CAC scores according to
nephropathy status, and the variables that were found
to be significantly associated with CAC score (gender,
age, number of antihypertensive medications, history of
CAD, and the duration of diabetes). When the analyses
were restricted to diabetic controls, 4 of these 5 factors
were significantly associated with the CAC score (gender,
age, number of antihypertensive medications, and history
of CAD). However, when the analyses were restricted to
individuals with DN (either after pooling the data for
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Latinos and African Americans, or in the 2 racial/ethnic
groups separately), none of these 5 factors were associ-
ated with CAC score.
The unadjusted geometric mean CAC score (ignoring
other subject characteristics associated with CAC score)
among individuals with DN was 5.2 times greater than di-
abetic controls (57.2 vs. 11.1, P = 0.002) (Table 4). Upon
adjusting the data for the differences in the mean number
of antihypertensive medications (DN 3.0 vs. diabetic con-
trols 1.2), the ratio of the geometric means of CAC scores
was attenuated to a nonsignificant 2-fold difference (39.5
vs. 19.7, P = 0.26) (Table 4). Thus, the apparent elevated
mean CAC score in DN subjects was associated with ev-
idence of more severe hypertension in this group.
There were no significant difference in the geometric
mean CAC scores between men with DN or diabetic con-
trols, or among women with DN (between 55 and 59);
however, the women diabetic controls had a significantly
lower mean score (Table 4). Among individuals >60 years
of age, there were no significant differences in the geomet-
ric mean CAC scores among DN and diabetic controls.
However, DN subjects in their 50s had a 6.1-fold greater
mean CAC than same-aged diabetic controls, and DN
subjects under 50 had a 9.0-fold greater mean CAC score
than same-aged diabetic controls (Table 4). There were
no significant differences in the geometric mean CAC
scores among individuals with DN, with or without CAD,
and among diabetic controls with CAD (between 43 and
126, Table 4). However, diabetic controls without CAD
had a significantly lower mean CAC score of 6 (Table 4).
Finally, regardless of the duration of diabetes, DN sub-
jects had a mean CAC scores about 4.5 times greater than
diabetic controls (Table 4).
These analyses were repeated after excluding African
Americans with DN, such that both the DN and control
groups comprised only Latino subjects. The results were
qualitatively unchanged: the unadjusted ratio of the ge-
ometric mean CAC among Latinos with DN to that of
diabetic controls was 7.0 (95% CI 2.1–23.0), and was 2.3
(95% CI 0.5–9.7; P = 0.27) when the data were adjusted
for the number of antihypertensive medications.
DISCUSSION
In this first such evaluation of nondialyzed individuals
with type 2 diabetes mellitus with and without DN, the
high prevalence and severity of CAC among individu-
als with DN could not be explained either by differences
in GFR or by various measures of disordered mineral
metabolism. On the other hand, it underscores the im-
portance of hypertension in contributing to high CAC
scores in the predialysis phase of diabetic renal disease.
Furthermore, this study suggests that the presence of DN
is associated with a substantial increase in the severity of
CAC among groups of subjects typically associated with
low cardiovascular risk—young individuals and females.
Various lines of evidence suggest that among individu-
als with end-stage renal disease undergoing maintenance
dialysis, disordered mineral metabolism plays an impor-
tant role in the severity of vascular calcification. These
lines of evidence include, but are not limited to, in vitro
evidence implicating phosphorus in inducing calcification
[33, 34], cross-sectional and longitudinal studies demon-
strating a relationship between serum calcium, phospho-
rus, and/or iPTH and severity of vascular calcification [4,
6–10, 35], and cross-sectional and longitudinal studies,
as well as a clinical trial, suggesting the contribution of
calcium-based phosphate binders [4, 5, 9, 36] to the high
calcification burden. On the other hand, studies in the
general population have failed to demonstrate any rela-
tionship between serum calcium-phosphorus product and
iPTH levels and severity of CAC [37, 38]; some, though
not all studies, have described an inverse association be-
tween serum 1,25 dihydroxy vitamin D levels [38–40].
This study explores, for the first time, the relationship be-
tween disordered mineral metabolism and CAC among
nondialyzed individuals at different stages of CKD.
Consistent with previous observations, this study
demonstrates that changes in serum levels of parathy-
roid hormone and 1,25-dihydroxy vitamin D levels are
apparent quite early in CKD, even when serum calcium
and phosphorus are normal [41]. Notwithstanding these
changes, this study also suggests that the high CAC bur-
den seen in nondialyzed individuals with DN is prob-
ably independent of disordered mineral metabolism or
its therapy. This is not surprising since the vast major-
ity (88%) of the patients with DN in our study had
serum phosphorus of ≤5.5 mg/dL. Thus, there was no pa-
tient who had been prescribed or was taking phosphate
binders, either at the time of or preceding the evalua-
tion. Even though most of the patients with DN (26/51)
had serum iPTH levels >150 pg/mL, none of the patients
were undergoing treatment with vitamin D or its analogs.
Consistent with these observations, there was no demon-
strable relationship between the GFR and the severity
of CAC. It may be argued that the present study did not
have sufficient power to detect the association between
the variables studied. However, there were sufficient sub-
jects to have 80% power to detect if any of the 4 measures
of disordered mineral metabolism explained at least 10%
of the variation in CAC with a P value of <0.05. Similarly,
the study had 80% power to determine if the variability
in GFR explains at least 12% of the CAC variation in DN
subjects. Another potential limitation is that the variables
analyzed in this study were measured only once. How-
ever, with progressive loss of GFR, disordered mineral
metabolism often worsens. Thus, the single value used
for analyses in this study probably overestimated the pre-
ceding exposure to the disordered mineral metabolism.
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Finally, it is possible that the role of the various measures
of disordered mineral metabolism in CAC may be modi-
fied by uremia-dependent or uremia-independent factors.
Such interactions were not studied or tested in this study
and, thus, cannot be excluded.
It follows, then, that among diabetic individuals, the
high prevalence and severity of CAC in the presence
of significant proteinuria cannot be explained by the
changes in GFR or disordered mineral metabolism. It
is possible that other cardiovascular risk factors that are
associated with the presence of proteinuria, independent
of GFR, may contribute to the high CAC burden among
individuals with DN. On the other hand, it is possible
that the same pathophysiologic mechanisms that lead to
proteinuria on one hand also lead to CAC.
In contrast to renal-related risk factors, when the data
were adjusted for the number of antihypertensive med-
ications, there were no significant differences in mean
CAC scores between patients with diabetes mellitus, with
and without nephropathy. The number of prescribed an-
tihypertensive medications is a surrogate, albeit crude,
measure of the severity of hypertension, since the mea-
sured blood pressure during the single clinic visit is sub-
stantially modified by therapy. Moreover, the number of
antihypertensive medications may represent the lifetime
exposure of the degree of hypertension. Thus, it is possi-
ble that a greater severity of hypertension may account
for the higher CAC burden among individuals with DN
compared to duration-matched, diabetic controls. Con-
sistent with this thesis, the secondary analyses from the
Irbersartan Diabetic Nephropathy Trial (IDNT) demon-
strated a significant relationship between achieved blood
pressure and cardiovascular events in individuals with di-
abetic nephropathy, underscoring the importance of hy-
pertension in contributing to cardiovascular disease in
this population [abstract; Berl T et al, J Am Soc Nephrol
14:5A, 2003].
In contrast to the importance of hypertension, the pres-
ence of DN appears to attenuate the importance of other
traditional risk factors like age and gender. With respect
to age, it is possible that restricting the study to individ-
uals between the ages of 40 and 65 years may have par-
tially attenuated its relationship to CAC. However, the
presence of end-stage renal disease is known to dispro-
portionately increase the risk for cardiovascular mortal-
ity among young individuals [42, 43]. The substantially
higher risk for the severity of CAC conferred by DN
among younger individuals even at the predialysis phase
of the disease is consistent with the observations among
maintenance dialysis patients. With respect to gender, the
adverse effect of the presence of diabetes mellitus on the
cardiovascular risk or CAC is greater among women than
men [44–49]. Our study suggests that the attenuation of
gender differences may be limited to individuals with di-
abetes mellitus who also have DN. However, given the
modest sample size of this study, these findings need to
be confirmed in larger studies. Finally, there was no sig-
nificant relationship between various measures of dyslipi-
demia and the severity of CAC. The failure to show such
a relationship may be related to the cross-sectional study
design as well as modification of current lipid levels with
statin therapy.
Our observations extend the existing body of CKD
literature regarding vascular calcification beyond indi-
viduals with end-stage renal disease. These data suggest
that that the vascular calcification seen among individ-
uals with type 2 diabetes mellitus undergoing mainte-
nance dialysis therapy represents a composite of a process
that begins (is often severe and is probably unrelated to
disordered mineral metabolism) with the appearance of
proteinuria (or, although not tested here, possibly even
microalbuminuria), and that is accelerated when the
disease progresses to end-stage renal disease (possibly
related to disordered mineral metabolism and/or its treat-
ments). In addition to the traditional cardiovascular risk
factors, CKD and/or nephrotic syndrome are associated
with an increased prevalence and/or severity of non-
traditional risk factors [i.e., inflammation, hyperhomo-
cysteinemia, increased Lp(a)] for atherosclerosis [50].
Future studies are needed to assess the relative contri-
bution of nontraditional risk factors to the high calcifi-
cation burden observed among nondialyzed individuals
with DN. This may help explain the substantially greater
risk conferred by the presence of DN among younger
individuals and females.
Since this study was exploratory in nature, no formal
adjustments were made for performing multiple statisti-
cal comparisons. It is possible, then, that some of the re-
sults may reflect false-positive associations. Nevertheless,
the identification of the number of antihypertensive med-
ications as an explanation for the elevated CAC scores in
DN subjects was robust enough to maintain significance
even when such adjustments were made. Furthermore,
the factors that were identified as associated with CAC
in Table 4 are consistent: the presence of DN does not
appear to confer additional risk for the severity of CAC
among diabetics with traditional CV risk factors. On the
other hand, among individuals without the traditional risk
factors (i.e., female gender, young age, lower severity of
hypertension as assessed by the number of antihyperten-
sive drugs), the presence of DN significantly enhances
the severity of CAC. Furthermore, almost identical re-
sults were obtained when the analyses were restricted to
Latino subjects only, a reduction of one third in the size
of the study.
CONCLUSION
CAC is almost universally present and often severe
among nondialyzed individuals with DN. The appearance
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of proteinuria seems to be associated with a near-
universal presence of CAC (which is often severe) even
at relatively high levels of GFR. Consistent with these
observations, the high CAC burden among nondialyzed
individuals with DN is unlikely to be related to disordered
mineral metabolism. On the other hand, the strong influ-
ence of the severity of hypertension and the association of
manifest CAD with the severity of calcification may sug-
gest that, just like in the general population, the severity
of CAC may represent atherosclerosis. Furthermore, one
may posit that aggressive control of blood pressure in the
predialysis phase of disease may have a salutary effect
on cardiovascular outcomes among individuals with DN.
Longitudinal studies are necessary to confirm these find-
ings, and to determine the prognostic significance of CAC
in this population. Future studies also need to identify ad-
ditional risk factors for CAC, as well as devise therapeutic
strategies to prevent and/or retard the rate of progression
of CAC.
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